2020.05.11

iRECIST Overview

 

This time, we’d like to introduce you iRECIST. This criteria has been announced by the RECIST working group of the EORTC (European Agency for Research and Treatment of Cancer) in 2017.

 Immunotherapy has been trends in oncological treatment. iRECIST describes how to measure and assess tumor size in immunotherapy clinical trials. We summarized the outline of this guideline here.

 

Micron’s ViewPoint_iRECIST_Overview